sarcopenia, pancreatic diseases
Conditions
Interventions
All patients consenting to the study, with or without sarcopenia, will undergo rehabilitation with uniform goals, and the feasibility, safety efficacy, and perioperative complications of the rehabilit
Sponsors
Kochi Medical School
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients diagnosed with resectable pancreatic cancer by diagnostic imaging and undergoing initial radical resection for pancreatic cancer. 2) Performance Status (ECOG scale): 0 to 2 3) Age: 20 years or older (at the time of enrollment) 4) Patients expected to survive more than 3 months from the date of enrollment 5) Patients with major organ function (bone marrow, heart, lungs, kidneys, etc.) as determined by examination within 14 days prior to enrollment 6) Patients who are able to take oral intake 7) Patients whose written consent has been obtained from the patient
Exclusion criteria
Exclusion criteria: 1) Patients with obvious infection or inflammation (e.g., fever over 38.0 degrees Celsius) 2) Patients with serious cardiac complications (requiring hospitalization) or a history of such complications 3) Patients with serious complications (requiring hospitalization) such as intestinal paralysis, intestinal obstruction, diabetes mellitus, renal failure, and non-compensated liver cirrhosis 4) Patients with a large amount of ascites (moderate or greater, exceeding the pelvic cavity and accumulating in front of the liver on CT) or pleural effusion 5) Pregnant or lactating women or women of childbearing potential 6) Patients with paralysis of the extremities or other conditions that make assessment of sarcopenia difficult 7) Other patients deemed inappropriate for this study by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in grip strength before and after rehabilitation | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety of rehabilitation, implementation rate, and efficacy of non-primary endpoints. Short-term postoperative outcomes. Postoperative glycemic control. Biomarkers. Insulin resistance. Study subjects will include non-sarcopenic and sarcopenic patients. The subjects will be divided into two groups to compare the endpoints. | — |
Countries
Japan
Contacts
Public ContactKazune Fujisawa
Kochi Medical School Department of surgery
Outcome results
None listed